Your browser doesn't support javascript.
loading
SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants.
Tea, Fiona; Ospina Stella, Alberto; Aggarwal, Anupriya; Ross Darley, David; Pilli, Deepti; Vitale, Daniele; Merheb, Vera; Lee, Fiona X Z; Cunningham, Philip; Walker, Gregory J; Fichter, Christina; Brown, David A; Rawlinson, William D; Isaacs, Sonia R; Mathivanan, Vennila; Hoffmann, Markus; Pöhlman, Stefan; Mazigi, Ohan; Christ, Daniel; Dwyer, Dominic E; Rockett, Rebecca J; Sintchenko, Vitali; Hoad, Veronica C; Irving, David O; Dore, Gregory J; Gosbell, Iain B; Kelleher, Anthony D; Matthews, Gail V; Brilot, Fabienne; Turville, Stuart G.
Affiliation
  • Tea F; Brain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.
  • Ospina Stella A; The Kirby Institute, The University of New South Wales, Sydney, New South Wales, Australia.
  • Aggarwal A; The Kirby Institute, The University of New South Wales, Sydney, New South Wales, Australia.
  • Ross Darley D; St Vincent's Hospital, Sydney, New South Wales, Australia.
  • Pilli D; School of Medicine, St Vincent's Clinical School, The University of New South Wales, Sydney, New South Wales, Australia.
  • Vitale D; Brain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.
  • Merheb V; Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
  • Lee FXZ; Brain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.
  • Cunningham P; Brain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.
  • Walker GJ; St Vincent's Applied Medical Research, Sydney, New South Wales, Australia.
  • Fichter C; New South Wales Health Pathology, Sydney, Australia.
  • Brown DA; The Kirby Institute, The University of New South Wales, Sydney, New South Wales, Australia.
  • Rawlinson WD; Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
  • Isaacs SR; New South Wales Health Pathology, Sydney, Australia.
  • Mathivanan V; New South Wales Health Pathology, Sydney, Australia.
  • Hoffmann M; School of Medical Sciences, Biotechnology and Biomolecular Sciences and School of Women's and Children's Health, The University of New South Wales Sydney, New South Wales, Australia.
  • Pöhlman S; Serology and Virology Division (SAViD), NSW HP SEALS, Randwick, Australia.
  • Mazigi O; New South Wales Health Pathology, Sydney, Australia.
  • Christ D; The Kirby Institute, The University of New South Wales, Sydney, New South Wales, Australia.
  • Dwyer DE; Infection Biology Unit, German Primate Center, Göttingen, Germany.
  • Rockett RJ; Faculty of Biology and Psychology, Georg-August-University Göttingen, Göttingen, Germany.
  • Sintchenko V; Infection Biology Unit, German Primate Center, Göttingen, Germany.
  • Hoad VC; Faculty of Biology and Psychology, Georg-August-University Göttingen, Göttingen, Germany.
  • Irving DO; School of Medicine, St Vincent's Clinical School, The University of New South Wales, Sydney, New South Wales, Australia.
  • Dore GJ; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
  • Gosbell IB; School of Medicine, St Vincent's Clinical School, The University of New South Wales, Sydney, New South Wales, Australia.
  • Kelleher AD; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
  • Matthews GV; New South Wales Health Pathology, Sydney, Australia.
  • Brilot F; Centre for Infectious Diseases & Microbiology, Public Health, New South Wales Health Pathology, Institute of Clinical Pathology & Medical Research (ICPMR), Westmead, Sydney, New South Wales, Australia.
  • Turville SG; Marie Bashir Institute for Biosecurity, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
PLoS Med ; 18(7): e1003656, 2021 07.
Article in En | MEDLINE | ID: mdl-34228725
ABSTRACT
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibody neutralization response and its evasion by emerging viral variants and variant of concern (VOC) are unknown, but critical to understand reinfection risk and breakthrough infection following vaccination. Antibody immunoreactivity against SARS-CoV-2 antigens and Spike variants, inhibition of Spike-driven virus-cell fusion, and infectious SARS-CoV-2 neutralization were characterized in 807 serial samples from 233 reverse transcription polymerase chain reaction (RT-PCR)-confirmed Coronavirus Disease 2019 (COVID-19) individuals with detailed demographics and followed up to 7 months. A broad and sustained polyantigenic immunoreactivity against SARS-CoV-2 Spike, Membrane, and Nucleocapsid proteins, along with high viral neutralization, was associated with COVID-19 severity. A subgroup of "high responders" maintained high neutralizing responses over time, representing ideal convalescent plasma donors. Antibodies generated against SARS-CoV-2 during the first COVID-19 wave had reduced immunoreactivity and neutralization potency to emerging Spike variants and VOC. Accurate monitoring of SARS-CoV-2 antibody responses would be essential for selection of optimal responders and vaccine monitoring and design.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Neutralizing / SARS-CoV-2 Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: PLoS Med Journal subject: MEDICINA Year: 2021 Document type: Article Affiliation country: Australia

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Neutralizing / SARS-CoV-2 Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: PLoS Med Journal subject: MEDICINA Year: 2021 Document type: Article Affiliation country: Australia